Xencor, Inc. (XNCR)

18.95 -0.12 (-0.63%) At close: 04:00PM EDT

Xencor, Inc.

465 North Halstead Street
Suite 200
Pasadena, CA 91107
United States
626 305 5900
https://www.xencor.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 280

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Bassil I. Dahiyat Ph.D.	Co-Founder, CEO, President & Director	1.08M	N/A	1970
Dr. John R. Desjarlais Ph.D.	Executive VP of Research & Chief Scientific Officer	711.45k	N/A	1964
Ms. Celia E. Eckert J.D.	Senior VP, General Counsel & Corporate Secretary	646.25k	N/A	1973
Dr. Nancy Valente M.D.	Executive VP & Chief Development Officer	28.16k	N/A	1959
Mr. Bart Cornelissen	Senior VP & CFO	N/A	N/A	N/A
Mr. Charles Liles	Associate Director and Head of Corporate Communications & Investor Relations	N/A	N/A	N/A
Dr. Jeremy Grunstein Ph.D.	Senior Vice President of Business Development	N/A	N/A	N/A
Mr. Kirk Rosemark RAC	Senior Vice President of Regulatory Affairs & Quality Assurance	N/A	N/A	1965
Mr. Eric P. Kowack	Senior Vice President of Program Leadership & Alliance Management	N/A	N/A	N/A
Mr. Dane Vincent Leone C.F.A.	Senior VP of Corporate Strategy	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Corporate governance

Xencor, Inc.’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.